Replies to post #2183 on Synaptogenix Inc (SNPX)

[F1ash]

"PKC activator treatment combined with spatial memory training restored mushroom spines and mushroom spine synapses; rescued PKCe/a expression and PKC/HuD/BDNF signaling; and normalized memory to the levels seen in young rats. These effects were produced by treatment with either bryostatin or the PKCe-specific activator, DCP-LA. Bryostatin also reversed alterations in GABAergic inhibitory postsynaptic currents (IPSPs) in aged, learning-impaired rats. Thus, our results support the therapeutic potential of PKC activators when added to cognitive rehabilitation for inducing mushroom spine synaptogenesis and reversing memory decline associated with aging.






https://www.ncbi.nlm.nih.gov/m/pubmed/23545166/

So I would say the jury is still out.

I would love to know the details of the CUP patient's drug administration details. Did they tell them they were getting a miracle drug administered? It never pays to discount the power of positive thinking on the placebo effect.

We're gonna know pretty soon if Bryostatin is for real or not though so that's a plus.

[donsker]

Thanks to you, and F1ash, for focusing the science very well, and why byrostatin is so fascinating, if not paradigm shifting. But on the self-placebo effect among the CUPs, my understanding is that "false positive" isn't at play, the advanced nature of their illness doesn't make them cognitively aware enough to know what's going on. Or have I missed something?